GarudaBio is an oncology focused biotechnology company developing a unique approach to monoclonal antibody targeting of drug resistant, aggressive cancers that express integrin αvβ3. The company’s antibody based immunotherapy links the key oncogenic cancer cell target, integrin αvβ3, to engagement of tumor associated macrophages to kill αvβ3+ cancer cells. Compelling preclinical proof of concept has been demonstrated in lung cancers resistant to EGFR targeted therapies and αvβ3+ KRAS mutant addicted cancers (lung and pancreatic adenocarcinoma).
Company Details
- Founded
- -
- Address
- 15 W43rd St.,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.garudabio.com
- Keywords
- Lexington.
- HQ
- New York, NY
Garuda Bio, Llc Questions
Garuda Bio, Llc's website is http://www.garudabio.com
Garuda Bio, Llc's LinkedIn profile is https://www.linkedin.com/company/garuda-bio-llc
Garuda Bio, Llc's industry is
Biotechnology Research
Garuda Bio, Llc's top competitors are
Inozyme Pharma,
Bonito Biosciences,
Dynamicure Biotechnology,
Animerra,
Cbset,
Concerto Biosciences,
Cage Pharma, Inc.,
Chempartner,
Labshares,
General Fluidics Corporation.
Garuda Bio, Llc's categories are Biotechnology Research
Garuda Bio, Llc's founding year is 2017
